- Home
- KSS vs GYRE Comparison
KSS vs GYRE Comparison
Compare KSS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSS
- GYRE
- Stock Information
- Founded
- KSS 1962
- GYRE 2002
- Country
- KSS United States
- GYRE United States
- Employees
- KSS N/A
- GYRE N/A
- Industry
- KSS Department/Specialty Retail Stores
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- KSS Consumer Discretionary
- GYRE Health Care
- Exchange
- KSS Nasdaq
- GYRE Nasdaq
- Market Cap
- KSS 931.8M
- GYRE 897.1M
- IPO Year
- KSS 1992
- GYRE N/A
- Fundamental
- Price
- KSS $9.57
- GYRE $7.49
- Analyst Decision
- KSS Sell
- GYRE
- Analyst Count
- KSS 13
- GYRE 0
- Target Price
- KSS $8.38
- GYRE N/A
- AVG Volume (30 Days)
- KSS 7.6M
- GYRE 188.1K
- Earning Date
- KSS 08-27-2025
- GYRE 08-12-2025
- Dividend Yield
- KSS 5.22%
- GYRE N/A
- EPS Growth
- KSS N/A
- GYRE N/A
- EPS
- KSS 1.09
- GYRE 0.02
- Revenue
- KSS $16,072,000,000.00
- GYRE $100,643,000.00
- Revenue This Year
- KSS N/A
- GYRE $21.04
- Revenue Next Year
- KSS N/A
- GYRE $89.64
- P/E Ratio
- KSS $8.79
- GYRE $96.96
- Revenue Growth
- KSS N/A
- GYRE N/A
- 52 Week Low
- KSS $6.04
- GYRE $6.11
- 52 Week High
- KSS $23.09
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- KSS 63.47
- GYRE 42.81
- Support Level
- KSS $8.88
- GYRE $7.49
- Resistance Level
- KSS $10.05
- GYRE $7.80
- Average True Range (ATR)
- KSS 0.46
- GYRE 0.48
- MACD
- KSS 0.08
- GYRE 0.07
- Stochastic Oscillator
- KSS 77.12
- GYRE 40.48
About KSS Kohl's Corporation
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.